Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on June 11, 2025
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
GlobeNewswire
·
June 11, 2025
DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John Maraganore, Ph.D., to the Board of …
AGM Update
GlobeNewswire
·
June 11, 2025
Oxford, UK – 11 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, provides an update to coincide with its Annual General Meeting being held at 3pm BST today at Windrush Court, Oxford, UK. OXB has …
Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.
GlobeNewswire
·
June 11, 2025
WILLOWBROOK, Ill., June 11, 2025 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz" or the "Company"), a late-stage biopharmaceutical company developing innovative therapies for unmet medical needs in critical care and neurology, has announced a $25 million …
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
GlobeNewswire
·
June 11, 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, including two featured oral …
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
GlobeNewswire
·
June 11, 2025
FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, founder, president and chief executive officer …
Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device
GlobeNewswire
·
June 11, 2025
-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party …
Ligand Announces 2025 Investor Day in New York City
GlobeNewswire
·
June 11, 2025
JUPITER, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 9, 2025 at 10 a.m. Eastern Time at the Harvard Club. The event will …
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
GlobeNewswire
·
June 11, 2025
WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “us” and “our”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients …
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
GlobeNewswire
·
June 11, 2025
SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced preclinical data highlighting the potential of soquelitinib to treat systemic sclerosis …
Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S.
GlobeNewswire
·
June 11, 2025
MELBOURNE, Australia and INDIANAPOLIS, June 11, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that its next-generation PSMA-PET imaging1 agent for prostate cancer, Gozellix® (kit for …
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results
GlobeNewswire
·
June 11, 2025
NEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025. “We are pleased to have …
Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men’s Health Month
GlobeNewswire
·
June 11, 2025
Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health …
Cabaletta Bio Announces Proposed Public Offering of Securities
GlobeNewswire
·
June 11, 2025
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically …
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
GlobeNewswire
·
June 11, 2025
– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients – – All SLE …
Basecamp Research Announces Breakthrough Discovery of Over One Million New Species, Yielding Enormous New Database Purpose-Built for Generative Foundation Models in Biology
GlobeNewswire
·
June 11, 2025
Company’s multi-year biodiscovery programme, driven by strategic economic partnerships across 26 countries, has resulted in BaseDataTM, the largest and fastest growing database of new biological protein sequences - 9.8 billion - ever built New species data …
Spring Bio Solution Launches NCE Grid to decode Para IV Filing and First-to-File Opportunities
GlobeNewswire
·
June 11, 2025
SOMERSET, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution, a global leader in the comparator sourcing and clinical trial supplies, has launched NCE Grid, the world’s first free NCE-1 intelligence platform - built to decode, centralize, and …
LQpay Expands Compliant Surcharging Solution, Optimizing Payment Strategy for Healthcare Practices
GlobeNewswire
·
June 11, 2025
PLANTATION, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- LQpay, a leading provider of innovative patient payments and automation technology, announced the expansion of its end-to-end compliant credit card surcharging solution, empowering healthcare practices to …
CHESS Health Solutions' Pharmacist-Supported Hypertension Model Delivers 9:1 ROI, Improves Patient Outcomes
GlobeNewswire
·
June 11, 2025
Winston-Salem, NC, June 11, 2025 (GLOBE NEWSWIRE) -- CHESS Health Solutions today announced compelling results from its centralized, pharmacist-supported hypertension care model, an innovative approach in which pharmacists collaborate with clinicians to …
Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel therapeutics for depression and neuropsychiatric disorders
GlobeNewswire
·
June 11, 2025
Proceeds to advance potentially disruptive, fast-acting therapeutics for treatment-resistant depression and other neuropsychiatric disorders First-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from …
Elkedonia clôture un tour d’amorçage de 11 millions d’euros pour le développement de neuroplastogènes comme traitements novateurs contre la dépression et les troubles neuropsychiatriques
GlobeNewswire
·
June 11, 2025
Les fonds permettront d’avancer dans la découverte de traitements potentiellement disruptifs, à action rapide, pour la dépression résistante aux traitements et d'autres troubles neuropsychiatriques. Molécules « first-in-class », non addictives et non …